Loading clinical trials...
Loading clinical trials...
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
Conditions
Interventions
SD-809
Placebo
Locations
106
United States
Teva Investigational Site 145
Tuscaloosa, Alabama, United States
Teva Investigational Site 107
Anaheim, California, United States
Teva Investigational Site 108
Anaheim, California, United States
Teva Investigational Site 123
Glendale, California, United States
Teva Investigational Site 177
Imperial, California, United States
Teva Investigational Site 160
Irvine, California, United States
Start Date
October 31, 2014
Primary Completion Date
August 19, 2016
Completion Date
August 19, 2016
Last Updated
November 9, 2021
NCT06997198
NCT05859698
NCT05238701
NCT02198794
NCT02195700
NCT02064010
Lead Sponsor
Auspex Pharmaceuticals, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions